TY - JOUR
T1 - Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica
AU - Branger, Christine G.
AU - Torres-Escobar, Ascención
AU - Sun, Wei
AU - Perry, Robert
AU - Fetherston, Jacqueline
AU - Roland, Kenneth L.
AU - Curtiss, Roy
N1 - Funding Information:
We thank S. Straley for providing plasmid pHT-V. J. Kilbourne is thanked for her expert assistance with animal experiments. This work was supported by National Institutes of Health grant 5R01 AI057885.
PY - 2009/8/27
Y1 - 2009/8/27
N2 - The use of live recombinant attenuated Salmonella vaccines (RASV) synthesizing Yersinia proteins is a promising approach for controlling infection by Yersinia species. In this study, we constructed attenuated Salmonella strains which synthesize a truncated form of LcrV, LcrV196 and evaluated the immune response and protective efficacy elicited by these strains in mice against two other major species of Yersinia: Yersinia pseudotuberculosis and Yersinia enterocolitica. Surprisingly, we found that the RASV strain alone was sufficient to afford nearly full protection against challenge with Y. pseudotuberculosis, indicating the likelihood that Salmonella produces immunogenic cross-protective antigens. In contrast, lcrV196 expression was required for protection against challenge with Y. enterocolitica strain 8081, but was not sufficient to achieve significant protection against challenge with Y. enterocolitica strain WA, which expressed a divergent form of lcrV. Nevertheless, we are encouraged by these findings to continue pursuing our long-term goal of developing a single vaccine to protect against all three human pathogenic species of Yersinia.
AB - The use of live recombinant attenuated Salmonella vaccines (RASV) synthesizing Yersinia proteins is a promising approach for controlling infection by Yersinia species. In this study, we constructed attenuated Salmonella strains which synthesize a truncated form of LcrV, LcrV196 and evaluated the immune response and protective efficacy elicited by these strains in mice against two other major species of Yersinia: Yersinia pseudotuberculosis and Yersinia enterocolitica. Surprisingly, we found that the RASV strain alone was sufficient to afford nearly full protection against challenge with Y. pseudotuberculosis, indicating the likelihood that Salmonella produces immunogenic cross-protective antigens. In contrast, lcrV196 expression was required for protection against challenge with Y. enterocolitica strain 8081, but was not sufficient to achieve significant protection against challenge with Y. enterocolitica strain WA, which expressed a divergent form of lcrV. Nevertheless, we are encouraged by these findings to continue pursuing our long-term goal of developing a single vaccine to protect against all three human pathogenic species of Yersinia.
KW - LcrV
KW - Recombinant attenuated Salmonella vaccine
KW - Yersinia
UR - http://www.scopus.com/inward/record.url?scp=68349096228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68349096228&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2009.06.078
DO - 10.1016/j.vaccine.2009.06.078
M3 - Article
C2 - 19596407
AN - SCOPUS:68349096228
SN - 0264-410X
VL - 27
SP - 5363
EP - 5370
JO - Vaccine
JF - Vaccine
IS - 39
ER -